Department of Public Health Science, Division of Biostatistics & Bioinformatics, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Clin Transl Sci. 2020 Jul;13(4):818-825. doi: 10.1111/cts.12775. Epub 2020 Apr 3.
Since 2006, the US Congress has appropriated ~ 7 billion dollars in total toward the (CTSA) program of the National Institutes of Health (NIH), representing ~ 1.5% of the NIH total budget. There is no doubt this investment has led to substantial improvements in clinical and translational research, but the impact of these large NIH-sponsored awards to academic medical centers have largely been documented by anecdotal accomplishments. This paper provides a purely quantitative assessment of the impact of these awards on clinical trials registered on ClinicalTrials.gov. In particular, we find a dramatic increase in the number of registered clinical trials and clinical trial enrollment associated with the CTSA grant award. Additionally, the impact is shown to be magnified with the number of years of receiving CTSA funding.
自 2006 年以来，美国国会共向美国国立卫生研究院（NIH）的转化医学推进计划（CTSA）拨款约 70 亿美元，占 NIH 总预算的约 1.5%。毫无疑问，这项投资极大地推动了临床和转化研究的发展，但这些由 NIH 提供的大型资助对学术医疗中心的影响在很大程度上仅通过轶事证据来证明。本文对这些奖项对 ClinicalTrials.gov 上注册的临床试验的影响进行了纯粹的定量评估。具体而言，我们发现与 CTSA 拨款相关的注册临床试验数量和临床试验入组数量显著增加。此外，随着获得 CTSA 资金的年限增加，其影响也被放大。
